Moleculin reports FY2023 net loss of $29.8M; cash runway into Q4 2024

Moleculin Biotech, Inc.

Net loss $29.8M for fiscal year ended Dec 31, 2023; no revenue reported (pre-revenue biotech).
R&D expenses $19.5M, up $0.5M YoY driven by $1.5M WPD sublicense termination; G&A $10.0M, down $1.5M.
Cash and equivalents $23.6M at year-end; management expects runway into Q4 2024.
Closed $4.5M registered direct offering and private placement with institutional investor and insiders.
Positive interim Annamycin data in AML; plans to advance into pivotal Phase 2B/3 trial in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Moleculin Biotech, Inc. reported the fiscal year ended December 31, 2023 results: net income $29.8 million.

Period: the fiscal year ended December 31, 2023
Net income: $29.8 million
Result: reported results

Exact text from the filing

Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today reported its financial results for the fiscal year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-009047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.